江苏亚虹医药科技股份有限公司2025年半年度报告摘要

Core Viewpoint - The company has not yet achieved profitability and faces significant cumulative losses due to extensive investments in drug research and development, which are expected to continue in the coming years [1][1][1] Section Summaries Important Notes - The semi-annual report is a summary derived from the full report, and investors are encouraged to read the complete document for a comprehensive understanding of the company's performance and future plans [1][1] - The company has outlined various risk factors in its report, including the risk of not achieving profitability and the uncertainty surrounding clinical trial outcomes for its research products [1][1] Company Overview - The company is identified as Jiangsu Yahon Pharmaceutical Technology Co., Ltd., with stock code 688176 and is listed on the Shanghai Stock Exchange [2][2] Financial Data - The report includes key financial data, although specific figures are not provided in the excerpts [3] Significant Events - The company held a meeting of its supervisory board on August 28, 2025, to discuss and approve the semi-annual report and related documents, ensuring compliance with legal and regulatory requirements [4][5] - The supervisory board confirmed the authenticity and completeness of the semi-annual report [5][6] Fundraising and Usage - The company raised a total of RMB 2,527.8 million through its initial public offering, with a net amount of RMB 2,380.59 million after expenses [14][15] - As of June 30, 2025, the company has established a management system for the use of raised funds, ensuring compliance with relevant regulations [16][17] - The company has utilized part of its idle funds for cash management, with a balance of RMB 1,115 million as of June 30, 2025, and has generated returns of RMB 1.946 million from these investments [21][22] Changes in Governance - The company has decided to abolish its supervisory board, transferring its responsibilities to the audit committee of the board of directors, in accordance with updated regulations [32][33] - The registered capital of the company has been adjusted from RMB 570 million to RMB 571.17 million following the completion of a stock incentive plan [34]